- Patients with late-stage, metastatic cancers
- NOX66 in combination with carboplatin
- No toxicity associated with NOX66
- Stabilisation of disease process
Sydney, 12 September 2017: Noxopharm (NOX:ASX) presented clinical data from its first-in-human clinical study of NOX66 to the European Society of Medical Oncology Annual Conference in Madrid (Spain) on 11th September 2017.
For further information please download PDF attached:
Download this document
